The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.
about
Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Management of the kidney transplant patient with chronic hepatitis C infectionA single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.CYP3A4 polymorphism and lopinavir toxicity in an HIV-infected pregnant woman.
P2860
The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The pharmacokinetics and pharm ...... ersons requiring hemodialysis.
@en
The pharmacokinetics and pharm ...... ersons requiring hemodialysis.
@nl
type
label
The pharmacokinetics and pharm ...... ersons requiring hemodialysis.
@en
The pharmacokinetics and pharm ...... ersons requiring hemodialysis.
@nl
prefLabel
The pharmacokinetics and pharm ...... ersons requiring hemodialysis.
@en
The pharmacokinetics and pharm ...... ersons requiring hemodialysis.
@nl
P2093
P2860
P1433
P1476
The pharmacokinetics and pharm ...... ersons requiring hemodialysis.
@en
P2093
Lynda A Szczech
Samir K Gupta
Stephen D Hall
Susan L Koletar
Susan L Rosenkranz
Valerianna Amorosa
Yoninah S Cramer
P2860
P304
P356
10.1097/QAD.0B013E32830E011F
P407
P577
2008-10-01T00:00:00Z